Reduced adiponectin levels in patients with COVID-19 acute respiratory failure: A case-control study

Sean M Kearns, Katelyn W Ahern, James T Patrie, William B Horton, Thurl E Harris, Alexandra Kadl, Sean M Kearns, Katelyn W Ahern, James T Patrie, William B Horton, Thurl E Harris, Alexandra Kadl

Abstract

Hypoadiponectinemia is speculated to play a key role in the relationship between obesity and COVID-19 respiratory failure. However, only one study has examined adiponectin levels in COVID-19 patients, and none have investigated adiponectin levels strictly in patients with acute respiratory failure. In this study, we performed a retrospective case-control study of adipokine levels in patients with acute respiratory failure caused by either COVID-19 or other viral/bacterial source. All patients with COVID-19 respiratory failure in the University of Virginia Biorepository and Tissue Research database were included. We also selected patients with non-COVID-19 infectious respiratory failure from the same biorepository to serve as a comparison cohort. Plasma adipokine levels were measured on three occasions during the first 72 hours of hospitalization. Twelve patients with COVID-19 respiratory failure and 17 patients with other infectious respiratory failure were studied. Adiponectin levels were significantly lower in patients with COVID-19 respiratory failure, even after adjustment for age, sex, BMI, and other covariates. In conclusion, adiponectin levels appear to be reduced in COVID-19 respiratory failure. Larger studies are needed to confirm this report.

Keywords: COVID-19; adipokines; adiponectin; critical illness; metabolism; respiratory insufficiency.

Conflict of interest statement

All authors have no conflict of interests to declare or disclose.

© 2021 The Authors. Physiological Reports published by Wiley Periodicals LLC on behalf of The Physiological Society and the American Physiological Society.

Figures

FIGURE 1
FIGURE 1
Summary statistics (mean and standard deviation) for adipokine levels within the COVID‐19 and non‐COVID‐19 (i.e., other infectious) respiratory failure cohorts

References

    1. Anderson, M. R. , Geleris, J. , Anderson, D. R. , Zucker, J. , Nobel, Y. R. , Freedberg, D. , Small‐Saunders, J. , Rajagopalan, K. N. , Greendyk, R. , Chae, S.‐R. , Natarajan, K. , Roh, D. , Edwin, E. , Gallagher, D. , Podolanczuk, A. , Barr, R. G. , Ferrante, A. W. , & Baldwin, M. R. (2020). Body mass index and risk for intubation or death in SARS‐CoV‐2 infection: A retrospective cohort study. Annals of Internal Medicine, 173(10), 782–790. 10.7326/M20-3214
    1. Arita, Y. , Kihara, S. , Ouchi, N. , Takahashi, M. , Maeda, K. , Miyagawa, J.‐I. , Hotta, K. , Shimomura, I. , Nakamura, T. , Miyaoka, K. , Kuriyama, H. , Nishida, M. , Yamashita, S. , Okubo, K. , Matsubara, K. , Muraguchi, M. , Ohmoto, Y. , Funahashi, T. , & Matsuzawa, Y. (1999). Paradoxical decrease of an adipose‐specific protein, adiponectin, in obesity. Biochemical and Biophysical Research Communications, 257(1), 79–83. 10.1006/bbrc.1999.0255
    1. Carboni, E. , Carta, A. R. , & Carboni, E. (2020). Can pioglitazone be potentially useful therapeutically in treating patients with COVID‐19? Medical Hypotheses, 140, 109776–10.1016/j.mehy.2020.109776
    1. Caterino, M. , Gelzo, M. , Sol, S. , Fedele, R. , Annunziata, A. , Calabrese, C. , Fiorentino, G. , D’Abbraccio, M. , Dell’Isola, C. , Fusco, F. M. , Parrella, R. , Fabbrocini, G. , Gentile, I. , Andolfo, I. , Capasso, M. , Costanzo, M. , Daniele, A. , Marchese, E. , Polito, R. , … Castaldo, G. (2021). Dysregulation of lipid metabolism and pathological inflammation in patients with COVID‐19. Scientific Reports, 11(1), 2941. 10.1038/s41598-021-82426-7
    1. Choi, H. M. , Doss, H. M. , & Kim, K. S. (2020). Multifaceted physiological roles of adiponectin in inflammation and diseases. International Journal of Molecular Sciences, 21(4), 1219. 10.3390/ijms21041219.
    1. Fioravanti, A. , Tenti, S. , Bacarelli, M. R. , Damiani, A. , Gobbi, F. L. , Bandinelli, F. , Cheleschi, S. , Galeazzi, M. , & Benucci, M. (2019). Tocilizumab modulates serum levels of adiponectin and chemerin in patients with rheumatoid arthritis: potential cardiovascular protective role of IL‐6 inhibition. Clinical and Experimental Rheumatology, 37(2), 293–300.
    1. Force, A. D. T. , Ranieri, V. M. , Rubenfeld, G. D. , Thompson, B. T. , Ferguson, N. D. , Caldwell, E. , Fan, E. , Camporota, L. , Slutsky, A. S. , Antonelli, M. , Anzueto, A. , Beale, R. , Brochard, L. , Brower, R. , Esteban, A. , Gattinoni, L. , Rhodes, A. , Vincent, J.‐L. , Bersten, A. , … Pesenti, A. (2012). Acute respiratory distress syndrome: The Berlin Definition. JAMA, 307(23), 2526–2533.
    1. Frank, R. C. , Mendez, S. R. , Stevenson, E. K. , Guseh, J. S. , Chung, M. , & Silverman, M. G. (2020). Obesity and the risk of intubation or death in patients with coronavirus disease 2019. Critical Care Medicine, 48(11), e1097–e1101. 10.1097/CCM.0000000000004553
    1. Garcia, P. , & Sood, A. (2012). Adiponectin in pulmonary disease and critically ill patients. Current Medicinal Chemistry, 19(32), 5493–5500.
    1. Gordon, A. C. , Mouncey, P. R. , Al‐Beidh, F. , Rowan, K. M. , Nichol, A. D. , Arabi, Y. M. , Annane, D. , Beane, A. , van Bentum‐Puijk, W. , Berry, L. R. , Bhimani, Z. , Bonten, M. J. M. , Bradbury, C. A. , Brunkhorst, F. M. , Buzgau, A. , Cheng, A. C. , Detry, M. A. , Duffy, E. J. , Estcourt, L. J. , Derde, L. P. G. (2021). Interleukin‐6 receptor antagonists in critically Ill patients with Covid‐19 – Preliminary report. medRxiv, 2021, 2007.
    1. Gupta, S. , Wang, W. , Hayek, S. S. , Chan, L. , Mathews, K. S. , Melamed, M. L. , Brenner, S. K. , Leonberg‐Yoo, A. , Schenck, E. J. , Radbel, J. , Reiser, J. , Bansal, A. , Srivastava, A. , Zhou, Y. , Finkel, D. , Green, A. , Mallappallil, M. , Faugno, A. J. … STOP‐COVID Investigators . (2021). Association between early treatment with tocilizumab and mortality among critically Ill patients with COVID‐19. JAMA Internal Medicine, 181(1), 41–51.
    1. Konter, J. M. , Parker, J. L. , Baez, E. , Li, S. Z. , Ranscht, B. , Denzel, M. , Little, F. F. , Nakamura, K. , Ouchi, N. , Fine, A. , Walsh, K. , & Summer, R. S. (2012). Adiponectin attenuates lipopolysaccharide‐induced acute lung injury through suppression of endothelial cell activation. The Journal of Immunology, 188(2), 854–863. 10.4049/jimmunol.1100426
    1. Lockhart, S. M. , & O'Rahilly, S. (2020). When two pandemics meet: Why Is obesity associated with increased COVID‐19 mortality? Med (N Y), 1(1), 33–42. 10.1016/j.medj.2020.06.005
    1. Shimizu, H. , Oh, I. S. , Tsuchiya, T. , Ohtani, K. I. , Okada, S. , & Mori, M. (2006). Pioglitazone increases circulating adiponectin levels and subsequently reduces TNF‐alpha levels in Type 2 diabetic patients: A randomized study. Diabetic Medicine, 23(3), 253–257. 10.1111/j.1464-5491.2006.01776.x
    1. Summer, R. , Fiack, C. A. , Ikeda, Y. , Sato, K. , Dwyer, D. , Ouchi, N. , Fine, A. , Farber, H. W. , & Walsh, K. (2009). Adiponectin deficiency: a model of pulmonary hypertension associated with pulmonary vascular disease. American Journal of Physiology‐Lung Cellular and Molecular Physiology, 297(3), L432–438. 10.1152/ajplung.90599.2008
    1. van Zelst, C. M. , Janssen, M. L. , Pouw, N. , Birnie, E. et al (2020). Analyses of abdominal adiposity and metabolic syndrome as risk factors for respiratory distress in COVID‐19. BMJ Open Respiratory Research, 7(1), e000792. 10.1136/bmjresp-2020-000792.
    1. Veiga, V. C. , Prats, J. , Farias, D. L. C. , Rosa, R. G. , Dourado, L. K. , Zampieri, F. G. , Machado, F. R. , Lopes, R. D. , Berwanger, O. , Azevedo, L. C. P. , Avezum, Á. , Lisboa, T. C. , Rojas, S. S. O. , Coelho, J. C. , Leite, R. T. , Carvalho, J. C. , Andrade, L. E. C. , Sandes, A. F. , Pintão, M. C. T. … Scheinberg, P. (2021). Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ, 372, n84. 10.1136/bmj.n84

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj